India Globalization Capital, Inc. Announces the Creation of China Advisory Board
June 04, 2012 at 12:16 pm
Share
India Globalization Capital, Inc. announced the creation of an advisory board for China. The China Advisory Board comprises of the following individuals: Senior Advisor: Mr. Hua Zhang is an entrepreneur and business leader in the Chifeng region of Inner Mongolia. He graduated from the Chinese Central Party School where he studied economics and management. He is currently the Chairman and CEO of several companies including a real estate development company, chrysanthemum extract development as well as Iron ore mining. In 2001 he was recognized as the Outstanding Young Entrepreneur. Since 2003 he has served as the Vice Director of the Chifeng City Chamber of Commerce. Mr. BenQuan Li has over 30 years of mining experience and is a highly respected entrepreneur in the mining industry of Chifeng. He has operated, owned and invested in Lead, Zinc, and Iron ore mines in Inner Mongolia. He possesses a unique knowledge of the geology of the region having lived and worked in the mining sector for most of his career. He is currently the Chairman of Weng Niu Te County Huayin Mining and a member of the Chinese People's Political Consultative Conference (CPPCC) of Weng Niu Te County. Mr. BenQuan Li is a major stock holder of IGC. Mr. JingYu Mu has over 30 years of mining experience, and is a highly respected entrepreneur in the mining industry of Chifeng in Inner Mongolia. Mr. Li and Mr. Mu have worked together as partners for over 20 years. They are both considered role models for the local industry. From 1978 to 1998, Mr. Mu served as the Manager of Finance for the Weng Niu Te County Dong Zi Cave Lead-Zinc Company. From 1999 to 2010, he served as the General Manager of Weng Niu Te County Huanggutun Mining. From 2011 to present, he serves as the Chairman of Weng Niu Te County Long Xiang Kuang Ye Mining Company. Mr. Mu is a major stock holder of IGC.
IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimerâs disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimerâs disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimerâs cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimerâs disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimerâs. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimerâs cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
IGC PHARMA, INC. 
